These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 8765816)

  • 1. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy.
    Blaauw PJ; Smithuis OL; Elbers AR
    J Allergy Clin Immunol; 1996 Jul; 98(1):39-47. PubMed ID: 8765816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
    Müller U; Helbling A; Berchtold E
    J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
    Sturm G; Kränke B; Rudolph C; Aberer W
    J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Wasp and bee venom allergy].
    Knulst AC; de Maat-Bleeker F; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 1998 Apr; 142(16):889-92. PubMed ID: 9623183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venom immunotherapy for preventing allergic reactions to insect stings.
    Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stinging insect allergy: natural history and modification with venom immunotherapy.
    Reisman RE; Dvorin DJ; Randolph CC; Georgitis JW
    J Allergy Clin Immunol; 1985 Jun; 75(6):735-40. PubMed ID: 4008803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.
    van Halteren HK; van der Linden PW; Burgers JA; Bartelink AK
    J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 1):767-70. PubMed ID: 9438484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the allergenicity and antigenicity of yellow jacket and hornet venoms.
    Reisman RE; Mueller U; Wypych J; Elliott W; Arbesman CE
    J Allergy Clin Immunol; 1982 Mar; 69(3):268-74. PubMed ID: 6801104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy.
    Golden DB; Lawrence ID; Hamilton RH; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1992 Sep; 90(3 Pt 1):386-93. PubMed ID: 1527321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting.
    Blaauw PJ; Smithuis LO
    J Allergy Clin Immunol; 1985 May; 75(5):556-62. PubMed ID: 3989140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of venom immunotherapy.
    Hafner T; DuBuske L; Kosnik M
    Ann Allergy Asthma Immunol; 2008 Feb; 100(2):162-5. PubMed ID: 18320918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of hymenoptera venom immunotherapy.
    Kayikci H; Bostan OC; Tuncay G; Cihanbeylerden M; Damadoglu E; Karakaya G; Kalyoncu AF
    Allergy Asthma Proc; 2024 Jul; 45(4):268-275. PubMed ID: 38982604
    [No Abstract]   [Full Text] [Related]  

  • 16. The sting challenge test in Hymenoptera venom allergy: pros and cons.
    Bilò MB; Brianzoni MF; Garritani MS; Antonicelli L; Farabollini B; Bonifazi F
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):377-81. PubMed ID: 14768522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of immunotherapy with venom in children with allergy to insect stings.
    Valentine MD; Schuberth KC; Kagey-Sobotka A; Graft DF; Kwiterovich KA; Szklo M; Lichtenstein LM
    N Engl J Med; 1990 Dec; 323(23):1601-3. PubMed ID: 2098016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
    Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
    Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
    J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.